Question 1

Purpose of the Procedure

Accepted Answer

Accurate subtyping of endometrial adenocarcinoma. Identifying eligibility for targeted immunotherapy. Screening for Lynch syndrome through MMR protein testing. Guiding adjuvant therapy decisions like chemotherapy or radiation.

Question 2

Key Biomarkers Evaluated

Accepted Answer

p53 Protein: Distinguishes high-grade serous-like subtypes. PTEN Protein: Evaluates cellular growth pathways. MMR Proteins: Assesses DNA mismatch repair status for immunotherapy guidance.

Question 3

When is this test required?

Accepted Answer

Following an initial diagnosis of endometrial cancer via biopsy. For patients requiring personalized adjuvant treatment plans. To assess potential hereditary cancer risks within the family.

Precise Endometrial Cancer Subtyping - Immunohistochemistry for Endometrial Carcinoma (IHC)